PERSEUS --- 2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach

PERSEUS --- 使用全新的计算机断层扫描方法针对转移性疾病进行基于 2D 材料的多重肿瘤治疗

• 批准号: 10073017
• 金额: $ 28.3万
• 依托单位: QED FILM & STAGE PRODUCTIONS LTD
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10073017
• 关键词: PERSEUS; 2D; Material; Based; Multiple

PERSEUS is developing a novel nanotechnology-based cancer treatment for deep-seated, clinically unmanageable, drug-resistant, and metastatic tumours. Practical use of nanotechnology in clinical cancer care is still in its infancy, its full potential yet to be realised. The treatment is based on a novel nano-system (NS) made of multifunctional 2D-layered nanocrystals. The NS enables, under activation by computed tomography (CT) X-rays, an effective multimodal therapy with minimal or no adverse effects. This novel paradigm uses CT X-rays not to eradicate cancer, but to trigger and to image the NS that locally activates non-mutagenic oncolytic mechanisms. The therapeutic effect is due to the conversion of low energy X-rays from CT scanners into heat, reactive oxygen species, and radiosensitising agents. X-ray irradiation can also induce immunogenic cell death with the exposure or release of neo-antigens to trigger an anti-cancer immune response. The use of X-rays makes it possible to reach deep-seated tumours that are inaccessible by visible or near-infrared light-based therapies. In other words, CT is the spark that lights the match. This is a radical vision for an ambitious and high-risk project. The project targets a range of cancer types, including metastatic triple negative breast cancer, hepatocellular carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma. The NS is biocompatible and also totally inactive in the absence of CT radiation, i.e. the NS becomes active only where the CT beam is delivered, hence minimising side effects at distal sites. The therapy is agnostic to the type of cancer and to gender incidence because it doesn't affect the body biochemistry. This is a second change of paradigm. The vision behind PERSEUS is pursued by a multidisciplinary team composed of physicists, chemists, chemical engineers, biologists, physicians, pharmacologists, and radiologists, working together to develop an innovative nanotechnological approach to address unmet clinical needs.

PERSEUS正在开发一种新的基于纳米技术的癌症治疗方法，用于治疗深层次的、临床上难以控制的、耐药的和转移性肿瘤。纳米技术在临床癌症护理中的实际应用仍处于起步阶段，其全部潜力尚未实现。治疗是基于一种新的纳米系统（NS）的多功能二维层状纳米晶体。在计算机断层扫描（CT）X射线激活下，NS能够实现有效的多模式治疗，副作用极小或无副作用。这种新的范例使用CT X射线不是为了根除癌症，而是为了触发和成像局部激活非诱变溶瘤机制的NS。治疗效果是由于低能量X射线从CT扫描仪转化为热，活性氧和放射增敏剂。X射线照射还可以通过暴露或释放新抗原来诱导免疫原性细胞死亡，从而引发抗癌免疫应答。X射线的使用使得有可能到达可见光或近红外光治疗无法到达的深层肿瘤。换句话说，CT是点燃火柴的火花。这是一个雄心勃勃的高风险项目的激进愿景。该项目针对一系列癌症类型，包括转移性三阴性乳腺癌、肝细胞癌、结直肠癌、胰腺导管腺癌。NS具有生物相容性，并且在没有CT辐射的情况下也完全无活性，即NS仅在CT射束被输送的地方变得有活性，因此最大限度地减少了远端部位的副作用。这种疗法不受癌症类型和性别发病率的影响，因为它不影响身体的生物化学。这是第二次范式转变。PERSEUS背后的愿景是由物理学家，化学家，化学工程师，生物学家，医生，药理学家和放射学家组成的多学科团队所追求的，他们共同努力开发创新的纳米技术方法来解决未满足的临床需求。